BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Medicine by Design - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://mbd.ccrm.ca
X-WR-CALDESC:Events for Medicine by Design
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220706T143000
DTEND;TZID=America/Toronto:20220706T153000
DTSTAMP:20260405T145958
CREATED:20220615T184809Z
LAST-MODIFIED:20220622T143150Z
UID:17410-1657117800-1657121400@mbd.ccrm.ca
SUMMARY:Conversations in Convergence: Jesse Gillis\, PhD\, and Alaura Androschuk
DESCRIPTION:Note: We are excited to transition Conversations in Convergence from a virtual to an in-person event\, providing more opportunity for networking and potential collaboration.  \nJoin us for our Conversations in Convergence series\, which features interactive discussions between Medicine by Design researchers who study similar questions using different approaches. \nThe theme of this conversation will be\, “Immune modulation by extrinsic and environmental factors.” \nRegister now\n\nSpeakers \nAlaura Androschuk \, PhD candidate in Michael Sefton’s lab\, Institute of Biomedical Engineering and the Department of Chemical Engineering & Applied Chemistry. \nIdentifying signalling pathways underlying biomaterial-driven terminal axon growth using single nucleus RNA-sequencing \nAlaura Androschuk is a PhD candidate focusing on the use of biomaterials for endogenous repair of tissues\, specifically subcutaneous nerve regeneration. Under the supervision of  Michael Sefton\, she has focused in part on identifying the signalling pathways and cells underlying the biomaterial-driven repair of complex tissues using proteomics and single nucleus transcriptomics. \n\nJesse Gillis\, Associate Professor and Bassingthwaighte Chair in Integrative Physiology\, Department of Physiology\, University of Toronto. \nBuffered and unbuffered cell lineage variability \nJesse Gillis completed his undergraduate in Biophysics at the University of Toronto\, where he also received his PhD in Neuroscience in 2007. His post-doctoral training was done at the Centre for High-throughput Biology at UBC. There\, he focused on meta-analysis of expression data\, and particularly co-expression analysis\, which infers functionality between genes based on shared expression profiles\, a form of network analysis. Jesse joined the faculty of CSHL in 2012 with a central focus on improving network analysis. In 2017\, he was promoted to Associate Professor at CSHL with his work focusing on single cell analysis\, particularly in collaboration with researchers in the BRAIN Initiative Cell Census Network. In 2022\, Jesse returned to U of T as the inaugural Bassingthwaighte Chair in Integrative Physiology and a Medicine by Design investigator. \n\nAbout Conversations in Convergence\n\nThe goal is to foster cross-disciplinary discussions in support of convergence\, which is the integration of approaches from engineering\, science\, medicine and other fields to expand knowledge and spark innovation. The researchers will discuss how their unique perspectives\, knowledge and ideas inform their work\, and how their diverse approaches intersect and complement one another to advance regenerative medicine. \n 
URL:https://mbd.ccrm.ca/event/conversations-in-convergence-jessis-gillis-phd-and-alaura-androschuk/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Other Events
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220628T120000
DTEND;TZID=America/Toronto:20220628T130000
DTSTAMP:20260405T145958
CREATED:20211021T185953Z
LAST-MODIFIED:20211021T185953Z
UID:15647-1656417600-1656421200@mbd.ccrm.ca
SUMMARY:Adipose Biology Seminar Series
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/adipose-biology-seminar-series-11/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220627T140000
DTEND;TZID=America/Toronto:20220627T150000
DTSTAMP:20260405T145958
CREATED:20220322T171327Z
LAST-MODIFIED:20230119T133116Z
UID:16798-1656338400-1656342000@mbd.ccrm.ca
SUMMARY:Myogenesis Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/myogenesis-discussion-group-11/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220623T113000
DTEND;TZID=America/Toronto:20220623T123000
DTSTAMP:20260405T145958
CREATED:20220329T180510Z
LAST-MODIFIED:20220329T180510Z
UID:16858-1655983800-1655987400@mbd.ccrm.ca
SUMMARY:Modelling Cell Development & Regeneration Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/modelling-cell-development-regeneration-discussion-group-12/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220621T120000
DTEND;TZID=America/Toronto:20220621T130000
DTSTAMP:20260405T145958
CREATED:20220517T170108Z
LAST-MODIFIED:20220615T211439Z
UID:17239-1655812800-1655816400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Gilbert Bernier\, PhD - Université de Montréal
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Gilbert Bernier\, PhD\, Associate Professor in the Department of Neuroscience at Université de Montréal. \nThe title of this talk will be\, “Cone photoreceptor sheet transplantation for the treatment of macular degenerations” \nRegister now\nHybrid event\, with in-person and virtual options\n\nIn-person will be held at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.\nVirtual event links will be sent after registration.\n\n \nMore About Gilbert bernier:\nProfessor Gilbert Bernier performed is graduated studies in Molecular Biology at Montreal University where he characterized the gene mutated in the mouse neurological disorder dystonia musculorum. In 1997\, he moved to the Max-Planck Institute of Biophysical Chemistry in Germany to study developmental biology of the retina. Since 2001\, he is heading the laboratory of stem cell and developmental biology at Maisonneuve-Rosemont Hospital to exploit the potential of human pluripotent stem cells for the study and treatment of neurodegenerative diseases such as retinal degenerative diseases and Alzheimer’s disease. Professor Bernier has also contributed to the characterization of Polycomb group proteins function in brain cancer\, DNA repair\, and premature ageing. He is Professor at the Neuroscience Department of Montreal University since 2012. He is co-founder and CEO of StemAxonTM\, a Canadian corporation involved in the development of new treatments for neurodegenerative diseases. \n Learn more about Gilbert Bernier
URL:https://mbd.ccrm.ca/event/global-speaker-series-gilbert-bernier-phd-universite-de-montreal/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220609T130000
DTEND;TZID=America/Toronto:20220609T150000
DTSTAMP:20260405T145958
CREATED:20220509T192249Z
LAST-MODIFIED:20220512T104931Z
UID:17164-1654779600-1654786800@mbd.ccrm.ca
SUMMARY:Spotlight on Clinical Translation: Making the leap from the lab bench to Phase I Clinical Trials
DESCRIPTION:  \nJoin us for Spotlight on Clinical Translation: Making the leap from the lab bench to Phase I Clinical Trials\, hosted by The Stem Cell Network and Medicine by Design. \nThis workshop will provide investigators and trainees with a basic understanding of the clinical pipeline\, from essential pre-clinical studies to Phase I first in human trials. The invited speakers will review processes involved in clinical trial submission\, regulatory approval and product manufacturing. An interactive Q&A session will ensure participants can ask questions relevant to their research along with leveraging this opportunity to connect with clinical trial experts. \nClinical studies are a key element on the pathway of translational cell and gene therapies. It is\, therefore\, essential that principal investigators\, researchers\, trainees\, clinical research fellows and ecosystem partners working in Canada undertaking translational research have a thorough understanding of the clinical trial pipeline; focused specifically on the early phase clinical trial design processes. \nRegister now!\n\nRegistration deadline: \nAttendance at this event is limited; all those interested in participating must register by June 8\, 2022\, at 11:59 PM local time. \nView Agenda \n1:00-1:05 pm ET – Opening Remarks\nModerators: Harold Atkins and Darshan Brahmbhatt \n1:05-1:40 pm ET – Presentation by Natasha Kekre\, MD\, Hematologist\, The Ottawa Hospital Transplant and Cellular Therapy Program\, and Scientist\, Ottawa Hospital Research Institute \nPresentation title: Building the pre-CTA and CTA package for Phase I trials: Case study using CLIC CAR-T trial for relapsed/refractory CD19 positive hematologic malignancies \n1:45-2:10 pm ET – Presentation by Patrick Bedford\, MSc\, Managing Director\, weCANreg Consulting Group Inc. \nPresentation title: Leveraging a regulatory rerspective on your path to trials \n2:15-2:40 pm ET – Presentation by Linh Nguyen\, PhD\, Staff Scientist/Head\, Cell Manufacturing Team\, Tumor Immunotherapy Program\, Princess Margaret Cancer Centre \nPresentation title: Developing a cell manufacturing process for an early phase clinical trial \n2:40-2:45 pm ET – Break \n2:45-3:00 pm ET – General Discussion/Q&A session \n3:00 pm ET – Closing Remarks \n\n\nSpeaker and Chair Details \nSPEAKERS\nPatrick BedfordNatasha KekreLinh NguyenPatrick Bedford \nPatrick Bedford\, MSc – Managing Director\, weCANreg Consulting Group Inc. \nPatrick Bedford is an experienced and certified regulatory professional who is focused on facilitating global regenerative medicine development. He founded & operates weCANreg Consulting Group Inc.\, which provides regulatory strategy\, interaction\, and submission services. Furthermore\, Patrick is VP of Regulatory & Development at Artisan Bio\, which is a CRISPR-enabled multiplex cell engineering company making precision immunotherapies. In his spare time\, he remains an active educator and contributor to regulatory policy development. \nPrior to incorporating his own company and leading regulatory strategy at Artisan Bio\, Patrick developed regulatory consulting services for a regenerative medicine Network Centre of Excellence; planned 2 Canadian CAR-T New Drug Submissions; and led teams at Health Canada responsible for developing guidance for biosimilars\, transplant material\, and cell & gene therapies. While leading these policy initiatives at Health Canada\, Patrick also supported their Therapeutic Products Classification Committee; chaired the Cells\, Tissues\, and Organs Classification Committee; and championed international harmonization initiatives. \nPatrick completed an Honours Bachelor of Health Sciences degree at the University of Western Ontario\, a Master’s degree in Bioethics and Health Law at the University of Otago\, a Regulatory Affairs Certificate from the Regulatory Affairs Professional Society\, and is pursuing his MBA at the Jack Welch Management Institute. \nNatasha Kekre \nNatasha Kekre\, MD – Hematologist\, The Ottawa Hospital Transplant and Cellular Therapy Program\, and Scientist\, Ottawa Hospital Research Institute\n \nDr. Natasha Kekre has been appointed to the Department of Medicine in the Division of Hematology\, within the Transplant and Cellular Therapy Program at The Ottawa Hospital\, effective October 2015. She is also an associate scientist within the Ottawa Hospital Research Institute and an associate professor of medicine at the University of Ottawa. She completed her Bachelor’s in Science at the University of Windsor then obtained her medical degree from the University of Ottawa. She then trained at the University of Ottawa in Internal Medicine and Hematology. She went on to do a fellowship in stem cell transplantation at Dana Farber Cancer Institute in Boston\, MA with a Masters in Public Health from Harvard University. \nHer research is focused on developing early phase clinical trials and moving home grown therapeutic strategies into patients. She collaborates with a number of local investigators and scientists in Ottawa\, studying hematologic malignancies and blood and marrow transplant recipients more specifically. She collaborates with scientists and physicians across Canada to build a Canadian CAR-T cell platform (chimeric antigen receptor T cells are immune cells engineered to kill cancer cells)\, bringing this exciting new therapy to Canadian patients. Her other clinical research interests include improving transplant related outcomes and projects with an epidemiologic focus\, including but not limited to decision modeling and meta-analyses. \nShe also participates with a number of cooperative groups in North America including the Center for International Blood and Marrow Transplant Research\, the Canadian Blood and Marrow Transplant Group\, the American Society of Hematology and the American Society for Transplant and Cellular Therapy. \nLinh Nguyen \nLinh Nguyen\, PhD – Staff Scientist/Head\, Cell Manufacturing Team\, Tumor Immunotherapy Program\, Princess Margaret Cancer Centre \nDr. Linh Nguyen has led the Cell Manufacturing Team of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre since 2005. Dr. Nguyen obtained her PhD in Immunology at the University of Toronto and pursued postdoctoral studies at Harvard Medical School. Her interests include tumor immunology and immunotherapy. Her team has manufactured cell and gene therapy products for clinical trials such as tumor-infiltrating lymphocytes (TILs)\, dendritic cells and T cell receptor gene-engineered T cells. The team’s activities also include quality assurance\, quality control\, and preparation of regulatory submissions. \n \nCHAIR\nHarold AtkinsDarshan H. BrahmbhattHarold Atkins \nHarold Atkins\, MD – Attending Physician\, The Ottawa Hospital Transplant and Cell Therapy Program\, and Scientist\, Ottawa Hospital Research Institute \nDr. Harry Atkins is a physician of The Ottawa Hospital Transplant and Cell Therapy Program\, an Associate Professor of Medicine at the University of Ottawa\, and a scientist in the Ottawa Hospital Research Institute’s Center for Innovative Cancer Research. \nHe received his Bachelor of Medical Science degree and Medical Degree from the University of Ottawa followed by a rotating internship year at the Victoria General Hospital in Victoria BC. Specialty training in Internal Medicine was done at the University of Ottawa. Clinical and research fellowships in Hematology\, Stem Cell Transplantation and Experimental Hematology followed at the University of Washington and at the Ontario Cancer Institute. \nHe specializes in hematopoietic stem cell transplantation and has spearheaded the use of stem cell transplantation for immune repair to treat patients with severe autoimmune diseases including multiple sclerosis\, scleroderma\, myasthenia gravis and others. The outcome of a trial using autologous hematopoietic stem cell transplantation to treat multiple sclerosis was published in the Lancet in 2016. He ran a clinical trial exploring the role of hematopoietic stem cell transplantation in preventing organ transplant rejection. He is a member of a BiocanRx funded\, pan-Canadian consortium to develop and improve the accessibility of new chimeric antigen receptor T lymphocytes for the treatment of hematological cancers. He was awarded the OHRI’s Dr. Michel Chretien Researcher of the Year in 2016\, the Till and McCulloch Award from the Stem Cell Network in 2017 and was the co-recipient of the Canadian Blood Services Lifetime Achievement Award in 2019. \nDarshan H. Brahmbhatt \nDarshan H. Brahmbhatt – MA MB BChir MPhil MRCS MRCP CCDS\, Ted Rogers Centre for Heart Function and Ajmera Transplant Centre\, University of Toronto \nDr. Darshan H. Brahmbhatt is a cardiologist who joined the UoT & TGH HF/Transplant team as a clinical fellow from London\, UK in October 2019\, having completed his doctoral research at the Royal Brompton Hospital and heart failure/device implantation training before that at Royal Papworth Hospital\, Cambridge.  His research focusses on implementation of remote monitoring and digital health solutions to assist clinicians make better decisions in managing patients with heart failure. He is currently supported by TRANSFORM-HF in his post-doctoral studies.
URL:https://mbd.ccrm.ca/event/spotlight-on-clinical-translation-making-the-leap-from-the-lab-bench-to-phase-i-clinical-trials/
LOCATION:Virtual
CATEGORIES:Co-hosted Events
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220609T113000
DTEND;TZID=America/Toronto:20220609T123000
DTSTAMP:20260405T145958
CREATED:20211021T192247Z
LAST-MODIFIED:20211021T192308Z
UID:15677-1654774200-1654777800@mbd.ccrm.ca
SUMMARY:Modelling Cell Development & Regeneration Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/modelling-cell-development-regeneration-discussion-group-11/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220531T120000
DTEND;TZID=America/Toronto:20220531T130000
DTSTAMP:20260405T145958
CREATED:20211021T185847Z
LAST-MODIFIED:20211021T185920Z
UID:15645-1653998400-1654002000@mbd.ccrm.ca
SUMMARY:Adipose Biology Seminar Series
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/adipose-biology-seminar-series-10/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220530T150000
DTEND;TZID=America/Toronto:20220530T170000
DTSTAMP:20260405T145958
CREATED:20220428T214037Z
LAST-MODIFIED:20220517T140217Z
UID:17094-1653922800-1653930000@mbd.ccrm.ca
SUMMARY:Pitch Competition: Building a Biotech Venture program
DESCRIPTION:  \nRegister to join the audience at the 2022 Pitch Competition!\nJoin us in-person on May 30 for the Building a Biotech Venture Pitch Competition to learn how the next generation of regenerative and precision medicine researchers are preparing to translate their discoveries toward impact. \nWatch as six trainee-led teams from the University of Toronto and its affiliated hospitals pitch their ventures to an expert panel of judges. The winning team will receive $25\,000\, and the second-place team will receive $10\,000 in research funding to advance their product concept.  \nRegister now\nThe competition is the culmination of Medicine by Design’s Building a Biotech Venture program\, offered in partnership with Precision Medicine Initiative (PRiME)\, the Health Innovation Hub (H2i) and Talk Boutique. Over the last six months\, teams have worked with mentors to advance early-stage company concepts based on their research. \nCome cheer on these up-and-coming entrepreneurs as they showcase their innovative technologies! \nNOTE: This event will be held in-person in accordance with the University of Toronto’s COVID-19 policies. Masks are required in indoor spaces where physical distancing cannot be maintained. \n\nMeet the judges\nAlberto GalassoElla Korets-Smith Angela MacDonaldRobin QuirkAlberto Galasso \n \n  \nAlberto Galasso\, PhD\nProfessor of Strategic Management\nRotman School of Management\, University of Toronto\nRead more \nElla Korets-Smith  \n\nElla Korets-Smith\, MBA\, MSc\nChief Business Officer\, Virica Biotech\nRead more \nAngela MacDonald \nAngela McDonald\, PhD\nEntrepreneur-in-Residence\, Versant Ventures\nRead more \nRobin Quirk \nRobin Quirk\, PhD\, MBA\nVice President\, Technology Sourcing & Venture Development\, CCRM\nRead more \n\n\n\nMeet the teams\nAzane Therapeutics\nDelivering the promise of RNA therapy.\nLab: Institute of Biomedical Engineering and Department of Immunology\, University of Toronto \nThis company’s product\, a delivery vehicle for mRNA-based therapies\, has the potential to make it possible for rare diseases to be treated with mRNA. The platform could also apply to regenerative medicine treatments such as stem cell reprogramming and inflammatory disorders. \n\nDTPX Therapeutics\nDeveloping immunotherapy against hibernating drug tolerant cancer cells for colorectal cancer patients.\nLab: Princess Margaret Cancer Centre\, University Health Network; and Donnelly Centre for Cellular and Biomolecular Research\, University of Toronto. \nWhen individuals are treated for colorectal cancer with standard chemotherapy\, a cell population that’s resistant to treatment can “hibernate” and re-emerge after treatment\, causing the tumour to relapse. DTXP Therapeutics aims to create a platform that can selectively target these hibernating cells to reduce the chance of relapse\, potentially benefiting many types of cancer.\n \nGlusyn Diagnostics\nAutomated PCR-free diagnostic systems for rapid\, low-cost\, distributed usage.\nLab: Leslie Dan Faculty of Pharmacy\, University of Toronto. \nWith mastitis in dairy cows as a use-case\, this teams aims to develop automated PCR-free diagnostic systems that are shelf-stable and have low manufacturing costs.\n \nA2O\nReprogramming for recovery.\nLab: Division of Anatomy\, University of Toronto. \nA2O has developed a type of gene therapy to convert toxic brain cells back into healthy cells to treat chronic neurodegenerative disease such as multiple sclerosis and Alzheimer’s disease\, as well as acute neurological injuries such as spinal cord injury. This therapy allows for a targeted approach that can be tailored to disease type\, stage or severity.\n \nOne Drug\nEnabling next generation drugs.\nLabs: Leslie Dan Faculty of Pharmacy\, University of Toronto; Institute of Biomedical Engineering\, University of Toronto; and Department of Chemistry\, University of Toronto.\n \nDeveloping clinical point-of-care diagnostic devices that will enable clinicians and drug developers identify patients at risk of adverse drug reactions and/or suboptimal drug response based on their genetic makeup.\n \nScivance\nDeveloping therapeutics for rare disease.\nLab: Department of Chemical & Physical Sciences\, University of Toronto Mississauga \nOnly five percent of rare diseases have treatments\, and a substantial portion of these rare diseases are caused by genes called fusion oncogenes. This team is developing a proprietary algorithm and multi-disciplinary pipeline which lies at the intersection of medicinal chemistry\, structural biophysics and molecular biology\, which can help develop treatments for these disease drivers.
URL:https://mbd.ccrm.ca/event/pitch-competition-biotech-venture-2022/
LOCATION:Leslie Dan Pharmacy Building Room PB B250\, 144 College St\, Toronto\, M5S 3M2\, Canada
CATEGORIES:Co-hosted Events
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220530T140000
DTEND;TZID=America/Toronto:20220530T150000
DTSTAMP:20260405T145958
CREATED:20220322T171250Z
LAST-MODIFIED:20220322T171250Z
UID:16799-1653919200-1653922800@mbd.ccrm.ca
SUMMARY:Myogenesis Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/myogenesis-discussion-group-10/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220517T120000
DTEND;TZID=America/Toronto:20220517T130000
DTSTAMP:20260405T145958
CREATED:20220412T163857Z
LAST-MODIFIED:20220516T134308Z
UID:16939-1652788800-1652792400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Klavs Jensen\, PhD - Massachusetts Institute of Technology
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Klavs Jensen\, PhD\, Warren K. Lewis Professor\, Chemical Engineering\, and Professor\, Materials Science and Engineering\, Massachusetts Institute of Technology. \nThe title of this talk will be\, “Accelerating chemical development with automation and machine learning.” \n Register for this virtual event. \n \nMore About Klavs jensen:\nKlavs F. Jensen is Warren K. Lewis Professor in Chemical Engineering and Materials Science and Engineering at the Massachusetts Institute of Technology. From 2007- July 2015 he was the Head of the Department of Chemical Engineering. His research interests include on-demand multistep synthesis\, methods for automated synthesis\, and machine learning techniques for chemical synthesis and interpreting large chemical data sets. He is a co-director of MIT’s consortium\, Machine Learning for Pharmaceutical Discovery and Synthesis\, which aims to bring machine learning technology into pharmaceutical discovery and development. Professor Jensen is a member of the US National Academy of Sciences\, the US National Academy of Engineering as well as the American Academy of Arts and Science. He is a Fellow of the American Association for the Advancement of Science (AAAS)\, and the American Institute of Chemical Engineers\, and the Royal Society of Chemistry. \n Learn more about Klavs Jensen’s lab
URL:https://mbd.ccrm.ca/event/global-speaker-series-klavs-jensen-phd-massachusetts-institute-of-technology/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220512T113000
DTEND;TZID=America/Toronto:20220512T123000
DTSTAMP:20260405T145958
CREATED:20211021T192226Z
LAST-MODIFIED:20211021T192226Z
UID:15675-1652355000-1652358600@mbd.ccrm.ca
SUMMARY:Modelling Cell Development & Regeneration Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/modelling-cell-development-regeneration-discussion-group-10/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220428T113000
DTEND;TZID=America/Toronto:20220428T123000
DTSTAMP:20260405T145958
CREATED:20211021T192139Z
LAST-MODIFIED:20211021T192139Z
UID:15673-1651145400-1651149000@mbd.ccrm.ca
SUMMARY:Modelling Cell Development & Regeneration Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/modelling-cell-development-regeneration-discussion-group-9/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220426T120000
DTEND;TZID=America/Toronto:20220426T130000
DTSTAMP:20260405T145958
CREATED:20211021T185824Z
LAST-MODIFIED:20211021T185824Z
UID:15643-1650974400-1650978000@mbd.ccrm.ca
SUMMARY:Adipose Biology Seminar Series
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/adipose-biology-seminar-series-9/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220425T140000
DTEND;TZID=America/Toronto:20220425T150000
DTSTAMP:20260405T145958
CREATED:20220103T161203Z
LAST-MODIFIED:20220103T161203Z
UID:16186-1650895200-1650898800@mbd.ccrm.ca
SUMMARY:Myogenesis Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/myogenesis-discussion-group-9/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220412T120000
DTEND;TZID=America/Toronto:20220412T130000
DTSTAMP:20260405T145958
CREATED:20220315T134520Z
LAST-MODIFIED:20220327T004408Z
UID:16729-1649764800-1649768400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Elmar Jaeckel\, MD - University Health Network
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Elmar Jaeckel\, MD\, Medical Director at the Liver Transplant Program\, Ajmera Transplant Centre at the University Health Network. \nThe title of this talk will be\, Tissue-specific tolerance by genetically modified regulatory T cells enables endogenous regeneration. \n Register for this virtual event. \nMore About elmar jaeckel:\nDr. Elmar Jaeckel is a trained gastroenterologist/hepatologist as well as endocrinologist/diabetologist and transplantation specialist. He is Medical Director of the Liver Transplant Program at the Transplant Centre\, University Health Network. Dr. Jaeckel studied medicine at University of Hamburg\, Yale University New Haven\, University of California San Diego\, University of Edinburgh and University of Sydney. He completed his medical training at the Hannover Medical School (MHH). He studied medical economics at the University of applied sciences in Hannover and received a bachelor as Medical Hospital Manager. Dr. Jaeckel spent a four years postdoctoral research fellowship with Harald von Boehmer at the Harvard Medical School/Joslin Diabetes Center\, Boston working on central and peripheral tolerance mechanisms in type 1 diabetes. Since 2003\, he has been leading the research group on immune tolerance and metabolic inflammation at the MHH. The group is focusing to establish tissue-specific tolerance in autoimmunity\, transplantation and metabolic inflammation. Since 2008 he is attending for gastroenterology\, hepatology\, endocrinology and diabetology at Hannover Medical School. \nDr. Jaeckel’s working group Immune Tolerance aims in establishing immune tolerance in type 1 diabetes and after biological beta cell replacement. For this purpose\, he is developing new cell and gene therapy approaches. He is involved in pursuing islet xenotransplantation in Germany and to facilitate tolerance to stem cell derived beta cells. One major research focus is the change of specificity of regulatory T cells for beta cells by the use of chimeric antigen-receptors (CARs). In addition\, he aims in local control of immune responses in metabolic inflammation in NASH patients. \nHe was co-chairing the collaborative research center transplantation for 12 years (CRC738)\, the CRC on xenotransplantation (CRC TR127) funded by the German Research Foundation and the Integrated Research Center Transplantation (IFB-Tx) funded by Federal Ministry for research and education. Besides this he received funding from the German Research Foundation\, Ministry of Health\, European Community\, Helmsley Foundation\, Juvenile Diabetes Research Foundation. \nDr. Jaeckel published numerous articles on viral hepatitis\, autoimmune liver disease\, autoimmune diabetes and islet transplantation tolerance. He developed tissue-specific regulatory T cell therapies for local tolerance induction\, which are currently being tested in clinical trials. He has numerous patents on tolerance inducing therapies and is co-founder of Quell Therapeutics aiming to develop clinical therapies for tolerance induction with regulatory T cells.
URL:https://mbd.ccrm.ca/event/global-speaker-series-elmar-jaeckel-phd-university-health-network/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220406T100000
DTEND;TZID=America/Toronto:20220406T110000
DTSTAMP:20260405T145958
CREATED:20220317T202954Z
LAST-MODIFIED:20220322T155320Z
UID:16756-1649239200-1649242800@mbd.ccrm.ca
SUMMARY:Conversations in Convergence: Courtney Jones\, PhD and Sophie McGibbon-Gardner
DESCRIPTION:Join us for our Conversations in Convergence series which is an interactive discussions between Medicine by Design researchers who study similar questions using different approaches. \nThe goal is to foster cross-disciplinary discussions in support of convergence\, which is the integration of approaches from engineering\, science\, medicine and other fields to expand knowledge and spark innovation. The researchers will discuss how their unique perspectives\, knowledge and ideas inform their work\, and how their diverse approaches intersect and complement one another to advance regenerative medicine. \nOur speakers will be: \n\nCourtney Jones\, PhD – Scientist\, Princess Margaret Cancer Centre\, University Health Network and Assistant Professor\, Department of Medical Biophysics\, University of Toronto\nSophie McGibbon-Gardner – PhD Candidate\, Department of Physics\, University of Toronto\n\n\nEvent theme: Deciphering cancer heterogeneity and metabolomics using different approaches \nSpeaker Biographies: \nCourtney Jones is a Scientist at the Princess Margaret Cancer Centre\, University Health Network\, and Assistant Professor in the Dept. of Medical Biophysics at the University of Toronto. Professor Jones received her doctorate from New York University in 2014 studying mechanisms of therapy resistance in pediatric acute lymphoblastic leukemia. She continued her training as a postdoctoral fellow with Dr. Craig Jordan at the University of Colorado where she studied metabolic properties of leukemia stem cells (LSCs). \n  \n \nSophie is a PhD Candidate focusing on biophysics – particularly the dynamics of cells. She is from Nova Scotia\, where she completed her undergraduate degree in physics and discovered the power of using quantitative and computational approaches to better understand complex systems. As a PhD student\, she has used these approaches to identify underlying dynamics of cells when finding answers experimentally is difficult or impossible. She has focused on understanding heritable heterogeneity in cellular reprogramming and assessing the role of tumor cell fitness in cancer treatment. \n  \nRegister now
URL:https://mbd.ccrm.ca/event/conversations-in-convergence-courtney-jones-phd-and-sophie-mcgibbon-gardner-phd/
LOCATION:Ontario
CATEGORIES:Other Events
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220331T113000
DTEND;TZID=America/Toronto:20220331T123000
DTSTAMP:20260405T145958
CREATED:20211021T192039Z
LAST-MODIFIED:20211021T192039Z
UID:15669-1648726200-1648729800@mbd.ccrm.ca
SUMMARY:Modelling Cell Development & Regeneration Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/modelling-cell-development-regeneration-discussion-group-7/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220329T120000
DTEND;TZID=America/Toronto:20220329T130000
DTSTAMP:20260405T145958
CREATED:20211021T180533Z
LAST-MODIFIED:20211021T180533Z
UID:15638-1648555200-1648558800@mbd.ccrm.ca
SUMMARY:Adipose Biology Seminar Series
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/adipose-biology-seminar-series-8/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220328T140000
DTEND;TZID=America/Toronto:20220328T150000
DTSTAMP:20260405T145958
CREATED:20220103T161130Z
LAST-MODIFIED:20220103T161130Z
UID:16184-1648476000-1648479600@mbd.ccrm.ca
SUMMARY:Myogenesis Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/myogenesis-discussion-group-8/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220317T113000
DTEND;TZID=America/Toronto:20220317T123000
DTSTAMP:20260405T145958
CREATED:20211021T192016Z
LAST-MODIFIED:20211021T192016Z
UID:15667-1647516600-1647520200@mbd.ccrm.ca
SUMMARY:Modelling Cell Development & Regeneration Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/modelling-cell-development-regeneration-discussion-group-6/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220315T120000
DTEND;TZID=America/Toronto:20220315T130000
DTSTAMP:20260405T145958
CREATED:20220208T154825Z
LAST-MODIFIED:20220308T200651Z
UID:16479-1647345600-1647349200@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Anne Brunet\, PhD - Stanford University
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Anne Brunet\, PhD\, Professor of Genetics at Stanford University. \nThe title of this talk will be\, Mechanisms of Aging. \n Register for this virtual event. \n \nMore About anne brunet:\nDr. Brunet obtained her B.Sc. from the Ecole Normale Supérieure in Paris and her Ph.D. from the University of Nice\, France. She did her postdoctoral training with Dr. Michael Greenberg at Harvard Medical School. Dr. Brunet is interested in the molecular mechanisms of aging and longevity. She wants to understand the mechanism of neural stem cell aging. She also seeks to discover novel genes regulating longevity\, notably developing a new short-lived vertebrate\, the African killifish. Dr. Brunet has published over 80 peer-reviewed papers and reviews. She has received several awards\, including the Pfizer/AFAR Innovation in Aging Research Award and the Vincent Cristofalo “Rising Star” Award in Aging Research. She received a Pioneer Award and a Transformative Award from the NIH Director’s fund\, which supports scientists who propose pioneering and transforming approaches to major challenges in biomedical research. \n Learn more about Anne Brunet’s lab
URL:https://mbd.ccrm.ca/event/global-speaker-series-anne-brunet-phd-stanford-university/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220303T113000
DTEND;TZID=America/Toronto:20220303T123000
DTSTAMP:20260405T145958
CREATED:20211021T191902Z
LAST-MODIFIED:20211021T191902Z
UID:15665-1646307000-1646310600@mbd.ccrm.ca
SUMMARY:Modelling Cell Development & Regeneration Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/modelling-cell-development-regeneration-discussion-group-5/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220228T140000
DTEND;TZID=America/Toronto:20220228T150000
DTSTAMP:20260405T145958
CREATED:20220103T160751Z
LAST-MODIFIED:20220103T160751Z
UID:16181-1646056800-1646060400@mbd.ccrm.ca
SUMMARY:Myogenesis Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/myogenesis-discussion-group-7/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220223T140000
DTEND;TZID=America/Toronto:20220223T150000
DTSTAMP:20260405T145958
CREATED:20220208T154915Z
LAST-MODIFIED:20220215T182045Z
UID:16469-1645624800-1645628400@mbd.ccrm.ca
SUMMARY:Conversations in Convergence: Julien Muffat\, PhD\, and Chao Wang\, PhD
DESCRIPTION:Join us for our Conversations in Convergence series which is an interactive discussions between Medicine by Design researchers who study similar questions using different approaches. \nThe goal is to foster cross-disciplinary discussions in support of convergence\, which is the integration of approaches from engineering\, science\, medicine and other fields to expand knowledge and spark innovation. The researchers will discuss how their unique perspectives\, knowledge and ideas inform their work\, and how their diverse approaches intersect and complement one another to advance regenerative medicine. \nOur speakers will be: \n\nJulien Muffat\, PhD – Scientist\, Neurosciences and Mental Health Program\, The Hospital for Sick Children and Assistant Professor\, Department of Molecular Genetics\, University of Toronto\nChao Wang\, PhD – Scientist\, Biological Sciences Platform\, Sunnybrook Research Institute and Assistant Professor\, Department of Immunology\, University of Toronto\n\n\nEvent theme: Role of immune cells in brain health \n  \nThe Muffat Lab studies how genetic and environmental vulnerabilities intersect to cause neurological disorders. We develop novel 3D cultures derived from human pluripotent stem cells\, to study degenerative and developmental diseases of the brain. We focus on inflammatory triggers\, including viral aetiologies\, in Autism\, Multiple Sclerosis or Alzheimer’s disease. Our work aims to highlight the dominant role of glial cells\, including resident immune cells such as the microglia\, in establishing neuronal dysfunction. The CRISPR toolkit allows functional interrogation of disease-associated variants expressed in specific cell types\, and unbiased genome-wide screens of cellular states and resilience. \n  \n \nChao Wang (PhD) is an immunologist with expertise in immune cell regulation\, cellular metabolism and single cell transcriptomics. As a postdoctoral fellow\, she discovered a role of CD5Like in regulating T lymphocyte function by promoting a polyunsaturated lipidome and regulating the ligand-dependent transcriptional activity of Rorgt (Cell\, 2015); she also uncovered and validated a T cell exhaustion/dysfunction module driven by zine metabolism in melanoma (Cell\, 2016). Based on these findings\, Dr. Wang validated a novel computational tool that allows comprehensive analysis of metabolism using single cell transcriptomics (Cell\, 2021). Leveraging such tools\, cell biology and animal modelling\, the Wang lab focuses on elucidating the molecular mechanisms of how cellular metabolic circuitry supports immune cell function in shaping neuroinflammation in autoimmune\, neurodegenerative and psychiatric disorders. \nRegister now
URL:https://mbd.ccrm.ca/event/conversations-in-convergence-julien-muffat-phd-and-chao-wang-phd/
LOCATION:Ontario
CATEGORIES:Other Events
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220222T120000
DTEND;TZID=America/Toronto:20220222T130000
DTSTAMP:20260405T145958
CREATED:20211021T180508Z
LAST-MODIFIED:20211021T180508Z
UID:15637-1645531200-1645534800@mbd.ccrm.ca
SUMMARY:Adipose Biology Seminar Series
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/adipose-biology-seminar-series-7/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220217T113000
DTEND;TZID=America/Toronto:20220217T123000
DTSTAMP:20260405T145958
CREATED:20211021T191750Z
LAST-MODIFIED:20211021T191750Z
UID:15663-1645097400-1645101000@mbd.ccrm.ca
SUMMARY:Modelling Cell Development & Regeneration Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/modelling-cell-development-regeneration-discussion-group-4/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220215T120000
DTEND;TZID=America/Toronto:20220215T130000
DTSTAMP:20260405T145958
CREATED:20220114T175715Z
LAST-MODIFIED:20220519T003652Z
UID:16256-1644926400-1644930000@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Lior Zangi\, PhD - Icahn School of Medicine
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Lior Zangi\, PhD\, Associate Professor\, Cardiovascular Research Institute\, Genetics at Icahn School of Medicine. \nThe title of this talk will be\, mRNA-Based Approach for Treating Ischemic Heart Disease. \n Register for this virtual event. \n \nMore About Lior Zangi:\nLior Zangi\, PhD\, is an Associate Professor with Tenure at the Icahn School of Medicine at Mount Sinai\, New York. He completed his education and training at the Weizmann Institute of Science\, and Harvard University. He has established a new method\, mRNA based\, for gene delivery into skeletal and cardiac muscle. In the last year\, these mRNA delivery methods have been used for COVID19 vaccinations and promoting cardiovascular regeneration in ischemic heart disease. Currently\, Prof. Zangi’s laboratory investigates mRNA delivery method into healthy or unhealthy specific cell types and organs\, top fight different diseases such as heart failure and cancer. \n Learn more about Lior Zangi’s lab
URL:https://mbd.ccrm.ca/event/global-speaker-series-lior-zangi-phd-icahn-school-of-medicine/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220211T100000
DTEND;TZID=America/Toronto:20220211T113000
DTSTAMP:20260405T145958
CREATED:20220126T142048Z
LAST-MODIFIED:20220127T223003Z
UID:16365-1644573600-1644579000@mbd.ccrm.ca
SUMMARY:Breaking the Myth of Objectivity
DESCRIPTION:Medicine by Design’s Healthy and Inclusive Labs committee invites you to “Breaking the Myth of Objectivity\,” an event that will focus on the role of bias in quantitative data. The speakers will discuss why all good science should be equitable science\, along with practical and concrete tools to identify and account for biases in quantitative data. \n  \nRegister Now\nSpeakers\n \n  \n  \nHeather Krause\, PStat\nCEO\, We All Count and Datassist\, Inc. \n  \n  \n \n  \nAzadeh Yadollahi\, PhD\nSenior Scientist\, Toronto Rehabilitation Institute\,\nUniversity Health Network\nThematic Program Inequity Co-Lead\, Data Sciences Institute \n  \n  \n\nModerator\n \n  \nMolly Shoichet\, PhD\nChair\, Medicine by Design Healthy & Inclusive Labs Committee\nUniversity Professor & Michael E Charles Professor in Chemical Engineering\, University of Toronto
URL:https://mbd.ccrm.ca/event/breaking-objectivity/
LOCATION:Ontario
CATEGORIES:Workshops
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220203T113000
DTEND;TZID=America/Toronto:20220203T123000
DTSTAMP:20260405T145958
CREATED:20211021T191641Z
LAST-MODIFIED:20211021T191641Z
UID:15661-1643887800-1643891400@mbd.ccrm.ca
SUMMARY:Modelling Cell Development & Regeneration Discussion Group
DESCRIPTION:Please visit the discussion groups page for more information.
URL:https://mbd.ccrm.ca/event/modelling-cell-development-regeneration-discussion-group-3/
LOCATION:Online
CATEGORIES:Discussion Groups
END:VEVENT
END:VCALENDAR